

TAKAFULINK DANA EKUITI GLOBAL

All information as at 31 July 2024 unless otherwise stated


Semua maklumat adalah seperti pada 31 Julai 2024 melainkan jika dinyatakan

Objective / Objektif Dana

Takafulink Dana Ekuiti Global aims to provide capital appreciation by investing in Shariah-compliant investments with exposure to the global equity markets.

Takafulink Dana Ekuiti Global bertujuan untuk menyediakan peningkatan nilai modal dengan melabur dalam sekuriti patuh Syariah melalui pendedahan terhadap pasaran ekuiti global.

Where the Fund invests Komposisi Pelaburan Dana



Asset Allocation Peruntukan Aset


	% NAV
1 abrdn Islamic World Equity Fund	99.28
2 Cash, Deposits & Others	0.72

Fund Details / Maklumat Terperinci Dana

Investment Manager / Pengurus Pelaburan	Prudential BSN Takaful Berhad
Inception Date / Tarikh Diterbitkan	08/07/2019
Current Fund Size / Saiz Dana Terkini	RM37,470,587.35
Annual Fund Management Charge / Caj Pengurusan Dana Tahunan	1.5% p.a.
Current NAV / NAB Terkini	RM1.60788

How the Fund has performed / Prestasi Dana

Performance Graph / Jaduan Prestasi Dana
Takafulink Dana Ekuiti Global Vs. MSCI ACWI Islamic (Shariah) Index



Total Price Movement Over the Following Periods / Jumlah Pergerakan Harga Dalam Tempoh Tersebut

	1 month	3 months	6 months	1 year	3 years	5 years	Since Inception
Price Movement / Pergerakan Harga	-1.94%	0.90%	3.71%	12.33%	9.39%	60.80%	60.79%
Benchmark / Penanda Aras	-1.85%	1.25%	4.85%	13.13%	31.32%	83.91%	81.66%
Outperformance / Perbezaan Prestasi	-0.09%	-0.35%	-1.14%	-0.80%	-21.93%	-23.11%	-20.87%

TAKAFULINK DANA EKUITI GLOBAL

All information as at 31 July 2024 unless otherwise stated

Semua maklumat adalah seperti pada 31 Julai 2024 melainkan jika dinyatakan

Monthly Update / Laporan Bulanan Terkini

Fund Review & Strategy

The Fund returned -1.94% for the month, underperforming the benchmark return of -1.85% by 0.09%. Year-to-date, The Fund returned 7.41%, outperforming the benchmark return of 7.13% by 0.28%. Global equity markets had a mixed performance in July amid varied economic signals, central bank moves and corporate earnings reports. Early in the month, global stocks reached all-time highs, but stock markets then wobbled triggered by a global tech outage and heightened geopolitical tensions, before subsequently recovering by the end of the month. The volatility was also in part due to disappointing earnings results from several US technology giants as investors became increasingly concerned about high valuation levels in technology shares. It was also a busy month for global central bank activity. ASML and NVIDIA were among the laggards, although there was no company-specific news. The underperformance in these holdings was likely driven by the ongoing tech rout and concern that the Biden administration may impose more trade restrictions with China. Elsewhere, Lululemon's shares continued to underperform on weak credit card data from the US and evidence that sportswear industry growth is decelerating. More positively, Lonza released results in late July that showed strong operating performance, with margins above expectations driven by its Small Molecules and Cell & Gene segments. The Biologics segment continued to see healthy contract signing. This was partially offset by underperformance in the Capsules & Health Ingredients segment. DSM Firmenich posted solid results with organic revenue at 7%, driven by strong volume growth. Perfumery & Beauty was the standout division with volumes up in the high teens. The Target Fund Manager also saw improved numbers in Animal Nutrition and Health. Elsewhere, the Target Fund's underweight position in Microsoft proved beneficial after a selloff in technology stocks as investors started to question valuations. The Target Fund's trading activity was muted.

Tinjauan & Strategi Dana

Dana mencatat pulangan -1.94% pada bulan ini, tidak mengatasi pulangan penanda aras -1.85% dengan perbezaan 0.09%. Sejak awal tahun sehingga kini, Dana memperoleh pulangan 7.41%, mengatasi pulangan penanda aras 7.13% dengan perbezaan 0.28%. Pasaran ekuiti global memberikan prestasi yang bercampur-campur pada Julai berikutan pelbagai isyarat ekonomi, pergerakan bank pusat dan laporan pendapatan korporat. Pada awal bulan, saham global mencecah paras tertinggi sepanjang masa, tetapi pasaran saham kemudian goyah, dicituskan oleh gangguan teknologi global dan ketegangan geopolitik yang meningkat, sebelum pulih menjelang akhir bulan. Ketidaktentuan itu juga sebahagiannya disebabkan oleh hasil pendapatan sebilangan gergasi teknologi AS yang mengecewakan kerana pelabur semakin bimbang tentang tahap penilaian tinggi saham teknologi. Ia juga merupakan bulan yang sibuk dengan aktiviti bank pusat global. ASML dan NVIDIA antara yang ketinggalan, walaupun tidak ada berita khusus tentang syarikat. Prestasi rendah melibatkan pegangan-pegangan ini mungkin didorong oleh kesuraman teknologi yang berterusan dan kebimbangan tentang pentadbiran Biden yang mungkin mengenakan lebih banyak sekatan perdagangan ke atas China. Di tempat lain, saham Lululemon terus berprestasi rendah atas data kad kredit yang lemah dari AS dan bukti bahawa pertumbuhan industri pakaian sukan semakin merosot. Lebih positif, Lonza mengumumkan keputusan pada akhir Julai yang menunjukkan pencapaian operasi yang kukuh, dengan margin melebihi jangkaan, didorong oleh segmen Molekul Kecil dan Sel & Gen. Segmen Biologi terus merakamkan pemeteraian kontrak yang sihat. Sebahagian perkembangan ini ditampai oleh prestasi segmen Kapsul & Ramuan Kesihatan yang hambar. DSM Firmenich mencatatkan keputusan kukuh dengan hasil organik pada 7%, didorong oleh pertumbuhan volum yang kukuh. Wangian & Kecantikan merupakan bahagian yang menonjol dengan peningkatan volum yang tinggi. Pengurus Dana Sasaran juga melihat angka Pemakanan dan Kesihatan Haiwan yang bertambah baik. Di tempat lain, kedudukan Dana Sasaran yang kekurangan pegangan dalam Microsoft terbukti bermanfaat selepas penjualan saham teknologi apabila pelabur mula mempersoalkan penilaian. Aktiviti dagangan Dana Sasaran lengang.

Source / Sumber: Fund Commentary, July 2024, N/A

Disclaimer

Investments are subject to investment risks including the possible loss of the principal amount invested. The value of the units may fall as well as rise. Past performances of the funds and that of the fund managers are not necessarily indicative of future performance. The price movements indicated are not reflective of the actual return on your investments (which are subject to your premium allocation rate and deduction charges). The actual return on your invested premiums may fluctuate based on the underlying performance of the investment-linked funds. All Takafulink Dana are invested in Shariah-approved securities and/or Islamic private debt securities. This leaflet is for illustrative purposes only. For further details on the terms and conditions, please refer to the policy document. For further details on how you can invest in these funds, please refer to the respective product brochures. In the event of discrepancy between the information in this fact sheet and the policy document, the information in the policy document shall prevail.

Pelaburan adalah tertakluk kepada risiko-risiko pelaburan termasuk kemungkinan kehilangan jumlah wang pokok yang dilabur. Nilai unit mungkin naik ataupun jatuh. Prestasi masa dulu dana-dana atau pengurus-pengurus dana tidak semestinya mencerminkan prestasi masa depan. Pergerakan harga yang ditunjukkan tidak menggambarkan pulangan sebenar pelaburan anda (yang tertakluk kepada kadar peruntukan premium dan caj potongan). Pulangan sebenar ke atas premium yang anda labur mungkin berbeza, bergantung kepada prestasi dana-dana). Semua Takafulink Dana dilaburkan dalam sekuriti yang diluluskan oleh Syariah dan/atau sekuriti hutang swasta Islam. Risalah ini disediakan hanya untuk gambaran semata-mata. Sila rujuk kepada dokumen polisi untuk keterangan lanjut mengenai terma-terma dan syarat-syarat. Untuk keterangan lanjut mengenai bagaimana anda boleh melabur dalam dana-dana ini, sila rujuk kepada risalah-risalah produk yang berkenaan. Jika terdapat perbezaan di antara helaian fakta dan dokumen polisi, maklumat dalam dokumen polisi dianggap muktamad.

PRUDENTIAL BSN

TAKAFUL